Vanda Pharmaceuticals, Inc. (VNDA)
-NasdaqGM 6.97 
0.12(1.69%) 4:00PM EDT|After Hours
:
6.97 0.00 (0.00%) 4:31PM EDT
| Prev Close: | 7.09 |
|---|
| Open: | 7.13 |
|---|
| Bid: | 6.64 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 8.75 |
|---|
| Beta: | 1.63 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 6.81 - 7.53 |
|---|
| 52wk Range: | 2.92 - 7.53 |
|---|
| Volume: | 932,957 |
|---|
| Avg Vol (3m): | 348,124 |
|---|
| Market Cap: | 197.57M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.85 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- VANDA PHARMACEUTICALS INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Vanda Pharmaceuticals price target raised to $17 from $11 at Lazard Capitalat theflyonthewall.com(Fri, May 17)
- Vanda Pharmaceuticals price target raised to $17 from $11 at Lazard Capitaltheflyonthewall.com(Fri, May 17)
- VANDA PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- Vanda Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
- Vanda Pharmaceuticals Earnings: Here’s Why Shares are Up Nowat Wall St. Cheat Sheet(Thu, May 9)
- Vanda Pharmaceuticals Inc. Earnings Call scheduled for 10:00 am ET todayCCBN(Thu, May 9)
- Q1 2013 Vanda Pharmaceuticals Inc. Earnings Release - Before Market OpenCCBN(Thu, May 9)
- Vanda Pharmaceuticals Reports First Quarter 2013 ResultsPR Newswire(Thu, May 9)
- VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements anEDGAR Online(Thu, May 9)
- Vanda Pharmaceuticals: Here’s What Investors Need to Know Before Earningsat Wall St. Cheat Sheet(Wed, May 8)
- VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EEDGAR Online(Sun, Apr 28)
- Why Did Vanda Pharmaceuticals Hit A 52-Week High?at Seeking Alpha(Fri, Apr 19)
- Vanda Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 9, 2013PR Newswire(Thu, Apr 18)
- Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical OfficerPR Newswire(Wed, Apr 17)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 6.15 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.91 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.22 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | -0.39 |
|---|
Business Summary
Vanda Pharmaceuticals Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders.
View More